Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies
Executive Summary
South Korea’s ABL Bio is tackling cancer and neurodegenerative diseases with its broad bispecific antibody pipeline and CEO Sang Hoon Lee outlines the firm’s multi-collaboration and licensing strategy.
You may also be interested in...
ABL’s Bispecific Antibody For Parkinson's Lands In Sanofi’s Hands
ABL Bio’s $1.06bn license deal with Sanofi for Parkinson's antibody is seen offering favorable terms to Korean biotech and is also poised to beef up French group’s presence in the space versus competitors.
Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC
Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.
Incentives, Novel Tech Seen Driving Multiple Korean IPOs In 2018
Despite an expected absence of large floats like that of Celltrion Healthcare last year, IPOs by biotech and pharma firms in South Korea are poised to rise in 2018 amid an improved stock listing environment and progress in novel drug development.